https://glp1telehealthreviews.com/news/A dated ledger of what changed for compounded and brand-name tirzepatide and semaglutide: provider price checks read on the providers' own pages, FDA actions on compounding, approvals and trial read-outs. Newest: Price Check, September 12: Embody, SnagRx and Yucca Health Verified on Their Own Pages and Ranked; the $119 Is a Non-Refundable Prepayment a.en-usSat, 12 Sep 2026 12:00:00 +0000 https://glp1telehealthreviews.com/news/#2026-09-12-price-check-embody-snagrx-yucca-verified-and-rankedhttps://glp1telehealthreviews.com/news/#2026-09-12-price-check-embody-snagrx-yucca-verified-and-rankedSat, 12 Sep 2026 12:00:00 +0000Five reads between September 4 and 12 closed the gap this site had carried since August 25: the three providers other comparison pages rank from citations are now recorded from their own plan pages, terms and refund policies, and they take the first, second and fifteenth places on the tirzepatide ranking. SnagRx and Embody share a $1,428 twelve-month total and a corporate parent (Modern Metabolic Medicine, Inc.); Trimi’s full ladder replaces a note that called its $235 month-to-month figure unsupported; NexLife’s microdose rows move from verified to reported because the plan tiles still print the prior card. https://glp1telehealthreviews.com/news/#2026-09-07-step-young-40-4-of-children-aged-6-to-11-on-semaglutide-no-lhttps://glp1telehealthreviews.com/news/#2026-09-07-step-young-40-4-of-children-aged-6-to-11-on-semaglutide-no-lMon, 07 Sep 2026 12:00:00 +0000Novo Nordisk reported topline phase 3 results on September 7, 2026: 165 children aged 6 to under 12 with obesity (more than 85% with class II or III obesity) were randomised to once-weekly semaglutide 1.7 mg or 2.4 mg by baseline weight or placebo, all with a reduced-calorie diet and increased activity, for 68 weeks with follow-up to 104 weeks. The primary endpoint — a greater BMI reduction than placebo — was met; 40.4% of treated children finished below the obesity threshold versus 0% on placebo. https://glp1telehealthreviews.com/news/#2026-09-02-hims-hers-faces-a-securities-class-action-built-on-the-ftc-chttps://glp1telehealthreviews.com/news/#2026-09-02-hims-hers-faces-a-securities-class-action-built-on-the-ftc-cWed, 02 Sep 2026 12:00:00 +0000Hagens Berman announced on September 2, 2026 that a securities class action has been filed against Hims & Hers Health on behalf of investors who bought shares between August 4, 2025 and July 29, 2026. The complaint tracks the FTC’s July 29 allegations — health data shared with advertising platforms, charges taken at intake before a clinician review, subscriptions enrolled without informed consent — and cites a $4.32 (14.7%) one-day share-price fall on July 29 that erased more than $970 million of market value. https://glp1telehealthreviews.com/news/#2026-09-01-nexlife-announces-flat-rate-september-cards-for-four-protocohttps://glp1telehealthreviews.com/news/#2026-09-01-nexlife-announces-flat-rate-september-cards-for-four-protocoTue, 01 Sep 2026 12:00:00 +0000A press release dated August 31, 2026 (distributed on GlobeNewswire September 1) restates NexLife’s standard cards — injectable tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 by term — and adds four ranges: microdose semaglutide $110–$129, microdose tirzepatide $129–$159, sublingual semaglutide $165–$199, sublingual tirzepatide $199–$229 per month, all “same price at every dose” with no membership fee. https://glp1telehealthreviews.com/news/#2026-08-28-fda-approves-mounjaro-tirzepatide-to-lower-cardiovascular-rihttps://glp1telehealthreviews.com/news/#2026-08-28-fda-approves-mounjaro-tirzepatide-to-lower-cardiovascular-riFri, 28 Aug 2026 12:00:00 +0000On August 28, 2026 the FDA added a cardiovascular indication to Mounjaro: lowering the risk of major adverse cardiovascular events (CV death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes at high risk, on the SURPASS-CVOT trial against Trulicity. https://glp1telehealthreviews.com/news/#2026-08-26-lilly-real-world-claims-study-links-zepbound-to-up-to-38-lowhttps://glp1telehealthreviews.com/news/#2026-08-26-lilly-real-world-claims-study-links-zepbound-to-up-to-38-lowWed, 26 Aug 2026 12:00:00 +0000Published in Diabetes, Obesity and Metabolism and announced by Lilly on August 26, 2026: 15,843 adults aged 55+ with obesity or overweight who started Zepbound were matched 1:1 with untreated controls in Komodo claims data. Costs were up to 15% lower ($181 per patient per month) at six months and up to 38% lower ($607) at twelve. The analysis excluded the price of Zepbound itself. https://glp1telehealthreviews.com/news/#2026-07-29-ftc-utah-and-los-angeles-county-sue-hims-hers-over-subscripthttps://glp1telehealthreviews.com/news/#2026-07-29-ftc-utah-and-los-angeles-county-sue-hims-hers-over-subscriptWed, 29 Jul 2026 12:00:00 +0000The Federal Trade Commission, joined by Utah and the Los Angeles County Counsel, filed suit in the Northern District of California on July 29, 2026, alleging Hims & Hers charged consumers on intake before any consultation, obstructed cancellation, and shared sensitive health data with Meta, Snap and other advertising platforms. https://glp1telehealthreviews.com/news/#2026-07-23-retatrutide-lilly-reports-21-23-weight-loss-in-triumph-2-andhttps://glp1telehealthreviews.com/news/#2026-07-23-retatrutide-lilly-reports-21-23-weight-loss-in-triumph-2-andThu, 23 Jul 2026 12:00:00 +0000Lilly’s triple-agonist retatrutide produced 21% average weight loss at 80 weeks in adults with type 2 diabetes (TRIUMPH-2) and 23% in adults with cardiovascular disease (TRIUMPH-3) at the highest doses, after 30% at 104 weeks in TRIUMPH-1 (May 2026). Lilly said it will seek FDA approval in the first quarter of 2027. https://glp1telehealthreviews.com/news/#2026-07-01-medicare-glp-1-bridge-begins-50-a-month-for-wegovy-zepbound-https://glp1telehealthreviews.com/news/#2026-07-01-medicare-glp-1-bridge-begins-50-a-month-for-wegovy-zepbound-Wed, 01 Jul 2026 12:00:00 +0000Medicare’s temporary GLP-1 Bridge started dispensing on July 1, 2026: a flat $50 copay for Wegovy (pill and injection), Zepbound (KwikPen) and Foundayo for Part D enrollees with a BMI of 35 or more, or 27 or more with a qualifying condition. The copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap. https://glp1telehealthreviews.com/news/#2026-06-26-fda-extends-the-comment-period-on-its-proposal-to-keep-semaghttps://glp1telehealthreviews.com/news/#2026-06-26-fda-extends-the-comment-period-on-its-proposal-to-keep-semagFri, 26 Jun 2026 12:00:00 +0000A Federal Register notice on June 26, 2026 (docket FDA-2018-N-3240) extended the comment period on the April 30 proposed determination by 30 days, to July 30, 2026. As of September 5, 2026 no final determination has been published; the proposal, not a final rule, is the current state. https://glp1telehealthreviews.com/news/#2026-05-18-fda-warning-letter-to-prorx-503b-outsourcing-facility-cited-https://glp1telehealthreviews.com/news/#2026-05-18-fda-warning-letter-to-prorx-503b-outsourcing-facility-cited-Mon, 18 May 2026 12:00:00 +0000The FDA cited ProRx for compounding tirzepatide using bulk API after tirzepatide came off the drug shortage list and without inclusion on the 503B Bulks List. The letter also documented sterility, labeling, and adverse-event reporting deficiencies. https://glp1telehealthreviews.com/news/#2026-04-30-fda-proposes-permanent-exclusion-of-semaglutide-tirzepatide-https://glp1telehealthreviews.com/news/#2026-04-30-fda-proposes-permanent-exclusion-of-semaglutide-tirzepatide-Thu, 30 Apr 2026 12:00:00 +0000The Federal Register notice (docket 2026-08552) would close the legal pathway that allowed 503B outsourcing facilities to compound GLP-1 medications at industrial scale, even if a future shortage is declared. The comment period, originally to June 29, 2026, was extended to July 30, 2026; no final determination had been published as of September 5, 2026. https://glp1telehealthreviews.com/news/#2026-04-01-foundayo-orforglipron-approved-first-new-molecule-oral-glp-1https://glp1telehealthreviews.com/news/#2026-04-01-foundayo-orforglipron-approved-first-new-molecule-oral-glp-1Wed, 01 Apr 2026 12:00:00 +0000Eli Lilly's once-daily oral GLP-1, branded Foundayo, was approved by the FDA on April 1, 2026 under the Commissioner's National Priority Voucher pilot and shipped from April 9, 2026 at $149 a month for the lowest dose on LillyDirect. It is the first oral GLP-1 receptor agonist FDA-approved for chronic weight management. https://glp1telehealthreviews.com/news/#2026-03-12-lilly-reports-a-reaction-related-impurity-in-all-10-compoundhttps://glp1telehealthreviews.com/news/#2026-03-12-lilly-reports-a-reaction-related-impurity-in-all-10-compoundThu, 12 Mar 2026 12:00:00 +0000Eli Lilly said on March 12, 2026 that it detected “significant levels” of a reaction-related impurity in every one of ten compounded tirzepatide products containing vitamin B12 obtained from compounding pharmacies, telehealth companies and med spas, notified the FDA, and asked for a nationwide recall of tirzepatide-B12 products. https://glp1telehealthreviews.com/news/#2026-03-09-hims-hers-stops-advertising-compounded-glp-1s-and-moves-its-https://glp1telehealthreviews.com/news/#2026-03-09-hims-hers-stops-advertising-compounded-glp-1s-and-moves-its-Mon, 09 Mar 2026 12:00:00 +0000On March 9, 2026 Hims & Hers announced a “strategic shift”: it would cease advertising compounded GLP-1 offerings, transition existing patients to FDA-approved alternatives where clinically appropriate, offer compounded medication only when a provider determines clinical necessity, and add Ozempic and Wegovy (pill and injection) from Novo Nordisk later that month. https://glp1telehealthreviews.com/news/#2026-03-03-fda-sends-30-warning-letters-to-telehealth-companies-over-mihttps://glp1telehealthreviews.com/news/#2026-03-03-fda-sends-30-warning-letters-to-telehealth-companies-over-miTue, 03 Mar 2026 12:00:00 +0000On March 3, 2026 the FDA issued 30 warning letters to telehealth companies for claims that compounded semaglutide and tirzepatide products are equivalent to, contain the same active ingredient as, or produce the same results as FDA-approved drugs, with 15 business days to correct the violations. https://glp1telehealthreviews.com/news/#2026-02-15-wegovy-label-expansion-metabolic-dysfunction-associated-steahttps://glp1telehealthreviews.com/news/#2026-02-15-wegovy-label-expansion-metabolic-dysfunction-associated-steaSun, 15 Feb 2026 12:00:00 +0000The FDA added a MASH indication to the Wegovy (semaglutide) label in early 2026, supported by ESSENCE trial data. The expansion broadens the FDA-approved GLP-1 indication set beyond weight management and OSA. https://glp1telehealthreviews.com/news/#2026-02-06-trumprx-launches-with-cash-prices-for-brand-glp-1s-zepbound-https://glp1telehealthreviews.com/news/#2026-02-06-trumprx-launches-with-cash-prices-for-brand-glp-1s-zepbound-Fri, 06 Feb 2026 12:00:00 +0000The TrumpRx cash-pay platform went live on February 6, 2026, listing manufacturer direct prices for FDA-approved GLP-1s: Zepbound from $299 (average about $346), Wegovy and Ozempic from about $150 (average about $399), Wegovy pill from $149. On February 9 Novo Nordisk filed a patent suit against Hims & Hers over a compounded semaglutide tablet. https://glp1telehealthreviews.com/news/#2026-02-06-fda-announces-intent-to-take-action-against-non-fda-approvedhttps://glp1telehealthreviews.com/news/#2026-02-06-fda-announces-intent-to-take-action-against-non-fda-approvedFri, 06 Feb 2026 12:00:00 +0000The February 6 press release confirmed that the agency would restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products and would pursue misleading direct-to-consumer advertising. https://glp1telehealthreviews.com/news/#2025-12-01-lilly-cuts-lillydirect-zepbound-vial-prices-to-299-399-449-ahttps://glp1telehealthreviews.com/news/#2025-12-01-lilly-cuts-lillydirect-zepbound-vial-prices-to-299-399-449-aMon, 01 Dec 2025 12:00:00 +0000On December 1, 2025 Eli Lilly lowered self-pay Zepbound single-dose vials on LillyDirect: 2.5 mg $299 (was $349), 5 mg $399 (was $499), and 7.5 mg through 15 mg $449 (was $499) under the Zepbound Self Pay Journey Program. Novo Nordisk had cut Wegovy and Ozempic cash prices to $349 in mid-November 2025 with a $199 introductory offer. https://glp1telehealthreviews.com/news/#2025-12-01-fda-cites-503b-outsourcing-facility-for-cgmp-violations-on-chttps://glp1telehealthreviews.com/news/#2025-12-01-fda-cites-503b-outsourcing-facility-for-cgmp-violations-on-cMon, 01 Dec 2025 12:00:00 +0000A 503B outsourcing facility in Cary, North Carolina received a CDER warning letter dated December 1, 2025 (publicly posted March 17, 2026) documenting multiple 503B and cGMP violations on compounded tirzepatide and semaglutide injections, including labeling deficiencies missing active ingredient identity, strength, and administration instructions. https://glp1telehealthreviews.com/news/#2025-09-16-fda-issues-55-warning-letters-to-online-sellers-of-compoundehttps://glp1telehealthreviews.com/news/#2025-09-16-fda-issues-55-warning-letters-to-online-sellers-of-compoundeTue, 16 Sep 2025 12:00:00 +0000On September 16, 2025, the FDA issued more than 55 warning letters to online sellers of compounded semaglutide and tirzepatide, citing misleading direct-to-consumer advertising as the primary basis. https://glp1telehealthreviews.com/news/#2025-01-15-fda-documents-455-adverse-event-reports-on-compounded-semaglhttps://glp1telehealthreviews.com/news/#2025-01-15-fda-documents-455-adverse-event-reports-on-compounded-semaglWed, 15 Jan 2025 12:00:00 +0000Many of the reports involve dosing errors from patients self-administering incorrect doses from multi-dose vials, including some requiring hospitalization. https://glp1telehealthreviews.com/news/#2024-12-20-zepbound-approved-for-obstructive-sleep-apnea-in-adults-withhttps://glp1telehealthreviews.com/news/#2024-12-20-zepbound-approved-for-obstructive-sleep-apnea-in-adults-withFri, 20 Dec 2024 12:00:00 +0000The FDA approved Zepbound (tirzepatide) in December 2024 for adults with moderate-to-severe obstructive sleep apnea and obesity, becoming the first prescription medication approved for OSA in the United States. https://glp1telehealthreviews.com/news/#2024-10-02-fda-confirms-tirzepatide-shortage-resolved-closing-the-503a-https://glp1telehealthreviews.com/news/#2024-10-02-fda-confirms-tirzepatide-shortage-resolved-closing-the-503a-Wed, 02 Oct 2024 12:00:00 +0000The FDA's October 2, 2024 statement that the tirzepatide shortage was resolved set in motion the regulatory cascade that culminated in the April 2026 503B Bulks-List exclusion proposal.